Biogen

This study offers kidney transplant patients with antibody-mediated rejection (AMR) the chance to receive felzartamab for up to 4 more years. AMR occurs when the immune system attacks the new kidney. The main goal is to check long-term safety and monitor kidney health through bio…

This Phase 2 study tests an experimental drug called BIIB080 in people with mild cognitive impairment or mild dementia due to Alzheimer's disease. The drug is injected into the fluid around the spinal cord every 12 or 24 weeks. Researchers want to see if it can slow the worsening…

This study tests a drug called litifilimab for people with lupus-related skin disease that didn't get better with standard antimalarial pills. About 450 adults with active skin lesions will receive either the drug or a placebo every 4 weeks for 24 weeks, then everyone gets the dr…

This study looks at the long-term safety of a drug called litifilimab for people with active lupus. About 864 adults who finished earlier studies will continue taking the drug for up to 3 years, along with their usual treatments. The goal is to see how safe it is and how well it …

This study tests a drug called felzartamab in people who received a kidney transplant and later developed antibody-mediated rejection (AMR), where the immune system attacks the new kidney. The drug targets immune cells that make harmful antibodies, aiming to reduce kidney damage …

This study tests a higher dose of nusinersen (Spinraza) in 45 teenagers and adults with spinal muscular atrophy (SMA) who cannot walk and have already taken risdiplam. Participants receive two 50 mg loading doses two weeks apart, then 28 mg every four months for about two years, …

This study tests omaveloxolone, a drug already approved for adults with Friedreich's ataxia, in children aged 2 to 15. Researchers want to see how the drug moves through children's bodies and whether it is safe. The study involves two parts: a single dose followed by daily dosing…

This study tests the long-term safety of the drug litifilimab in adults with lupus skin disease (CLE) that didn't improve with standard antimalarial treatment. About 322 participants who completed a prior study will receive injections every 4 weeks for up to 2 years (or 5 years i…

This phase 3 trial tests whether the drug tofersen can delay or prevent ALS in adults who carry a SOD1 gene mutation but have no symptoms yet. About 158 participants will receive either tofersen or a placebo, and researchers will track how many develop ALS within two years. The g…

This long-term study is testing higher doses of nusinersen (Spinraza) in people with spinal muscular atrophy who already completed a previous nusinersen study. The main goal is to check safety over several years, including side effects, heart health, and growth. Participants rece…

This phase 3 study tests litifilimab, an experimental drug, in 548 adults with active systemic lupus erythematosus (SLE) who are already on standard treatments. Participants receive either high or low doses of litifilimab or a placebo as injections every 4 weeks for 52 weeks. The…

This study tests a new drug called litifilimab for people with active systemic lupus erythematosus (SLE), a chronic autoimmune disease. About 562 adults already on standard lupus treatments will receive either litifilimab or a placebo as a shot every 4 weeks for 52 weeks. The goa…

This study tests a drug called BIIB017 (Plegridy) in teenagers aged 10 to 17 with relapsing-remitting multiple sclerosis (MS). It compares Plegridy to another MS drug, Avonex, to see which is safer and more effective at reducing relapses. The trial involves 152 participants and i…

This study observes over 1,100 pregnant women with multiple sclerosis to see if taking the drug diroximel fumarate (VUMERITY) affects their babies' health. Researchers will compare birth defects, miscarriages, preterm births, and stillbirths among women who took DRF, other MS dru…

This study tracks about 400 people with multiple sclerosis (MS) to see how many develop antibodies against the drug natalizumab when it is given as a shot under the skin. Researchers will also look at side effects and relapse rates in those who develop antibodies. The goal is to …

This study looks at the long-term safety of two multiple sclerosis (MS) medications, Vumerity and Tecfidera, by analyzing data from over 10,000 patients in large MS registries. The goal is to track serious side effects, including infections and cancer, and compare them to other M…

This study is a registry that collects information on up to 600 children in China with spinal muscular atrophy (SMA). It aims to describe how the disease progresses and how treatments are used in everyday medical practice. The study does not test a new drug but gathers data to be…